meta
|
evidence
oncology
Living systematic review and meta-analysis
locally advanced NSCLC - maintenance (M)
laNSCLC - M - all population
1
laNSCLC - M - EGFR mutant
immune chekpoint inhibitors
anti-PD-(L)1
durvalumab based treatment
durvalumab alone
versus all
vs non active control
vs placebo
All patients
Age < 65y (younger)
Age > 65y
Asian type
cell type, non squamous cell
cell type, squamous cell
ECOG 0
ECOG 1
EGFR mutant
Gender, female
Gender, male
PDL1 < 25%
PDL1 >25%
smoker (current or former)
smoker (never)
stage IIIa
stage IIIb
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
deaths (OS)
deaths (OS) (extension)
DOR
DOR (extension)
objective responses (ORR)
PFS (extension)
progression or deaths (PFS)
AE (any grade)
AE (grade 3-4)
AE leading to death (grade 5)
AE leading to treatment discontinuation (any grade)
SAE (any grade)
TRAE (any grade)
TRAE (grade 3-4)
TRAE leading to death (grade 5)
Asthenia TRAE (grade 3-4)
Cough TRAE (grade 3-4)
Decreased appetite TRAE (grade 3-4)
Diarrhoea TRAE (grade 3-4)
Dyspnoea TRAE (grade 3-4)
Hyperthyroidism TRAE (grade 3-4)
Hypothyroidism TRAE (grade 3-4)
Nausea TRAE (grade 3-4)
Pneumonitis TRAE (grade 3-4)
Pruritus TRAE (grade 3-4)
Rash TRAE (grade 3-4)
Anaemia AE (grade 3-4)
Arthralgia AE (grade 3-4)
Asthenia AE (grade 3-4)
Back pain AE (grade 3-4)
Constipation AE (grade 3-4)
Cough AE (grade 3-4)
Decreased appetite AE (grade 3-4)
Diarrhoea AE (grade 3-4)
Dyspnoea AE (grade 3-4)
Fatigue AE (grade 3-4)
Headache AE (grade 3-4)
Hypothyroidism AE (grade 3-4)
Nausea AE (grade 3-4)
Pneumonia AE (grade 3-4)
Pneumonitis AE (grade 3-4)
Pruritus AE (grade 3-4)
Pyrexia AE (grade 3-4)
Rash AE (grade 3-4)
deaths (OS)
progression or deaths (PFS)
RFS/DFS
laNSCLC - M - all population
locally advanced NSCLC - maintenance (M)
laNSCLC - M - all population
versus placebo
durvalumab alone vs. placebo
1
1.0
better
0.3
5.0
98 %
1.0
better
0.3
5.0
100 %
-
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open